Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Jelle Wesseling's publication output changed over time?
ScholarIQpublication output · 1995–2023
Output grew0% over the shown period — from 1 works in 1995 to 1 in 2023.
1
1
1
1
2
1
1
1
1
1
1995199620072010201420152017201820202023
What are the most-cited papers on Jelle Wesseling?
ScholarIQmost cited works
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
Fiona M. Blows, Kristy Driver, Marjanka K. Schmidt, Annegien Broeks, Flora E. van Leeuwen, Jelle Wesseling, Maggie C.U. Cheang, Karen A. Gelmon, Torsten O. Nielsen, Carl Blomqvist, Päivi Heikkilä, Tuomas Heikkinen, Heli Nevanlinna, Lars A. Akslen, Louis R. Bégin, William D. Foulkes, Fergus J. Couch, Xianshu Wang, Vicky Cafourek, Janet E. Olson, Laura Baglietto, Graham G. Giles, Gianluca Severi, Catriona McLean, Melissa C. Southey, Emad A. Rakha, Andrew R. Green, Ian O. Ellis, Mark E. Sherman, Jolanta Lissowska, William F. Anderson, Angela Cox, Simon S. Cross, Malcolm Reed, Elena Provenzano, Sarah‐Jane Dawson, Alison M. Dunning, Manjeet K. Humphreys, Douglas F. Easton, Montserrat García‐Closas, Carlos Caldas, Paul D.P. Pharoah, David G. Huntsman
PLoS Medicine. 20101,153 CitationsOPEN ACCESS
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun, Liqin Wang, Sidong Huang, Guus J.J.E. Heynen, Anirudh Prahallad, Caroline Robert, John B.A.G. Haanen, Christian U. Blank, Jelle Wesseling, Stefan M. Willems, Davide Zecchin, Sebastijan Hobor, Prashanth Kumar Bajpe, Cor Lieftink, Christina Mateus, Stéphan Vagner, Wipawadee Grernrum, Ingrid Hofland, Andreas Schlicker, Lodewyk F.A. Wessels, Roderick L. Beijersbergen, Alberto Bardelli, Federica Di Nicolantonio, Alexander M.M. Eggermont, René Bernards
Nature. 2014913 CitationsOPEN ACCESS
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.
Jelle Wesseling, S W van der Valk, Hans L. Vos, Arnoud Sonnenberg, John Hilkens
S96410829. 1995495 CitationsOPEN ACCESS
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
ABCTB Investigators, Roger L. Milne, EMBRACE, GEMO Study Collaborators, HEBON, kConFab/AOCS Investigators, NBSC Collaborators, Karoline Kuchenbaecker, Kyriaki Michailidou, Jonathan Beesley, Siddhartha Kar, Sara Lindström, Shirley Hui, Audrey Lemaçon, Penny Soucy, Joe Dennis, Xia Jiang, Asha Rostamianfar, Hilary K. Finucane, Manjeet K. Bolla, Lesley McGuffog, Qin Wang, Cora M. Aalfs, Marcia Adams, Julian Adlard, Simona Agata, Shahana Ahmed, Habibul Ahsan, Kristiina Aittomäki, Fares Al‐Ejeh, Jamie Allen, Christine B. Ambrosone, Christopher I. Amos, Irene L. Andrulis, Hoda Anton‐Culver, Natalia Antonenkova, Volker Arndt, Norbert Arnold, Kristan J. Aronson, Bernd Auber, Paul L. Auer, Margreet G.E.M. Ausems, Jacopo Azzollini, François Bacot, Judith Balmañà, Monica Barile, Laure Barjhoux, Rósa B. Barkardóttir, Myrto Barrdahl, Daniel R. Barnes, Daniel Barrowdale, Caroline Baynes, Matthias W. Beckmann, Javier Benı́tez, Marina Bermisheva, Leslie Bernstein, Yves‐Jean Bignon, Kathleen R. Blazer, Marinus J. Blok, Carl Blomqvist, William J. Blot, Kristie Bobolis, Bram Boeckx, Natalia Bogdanova, Anders Bojesen, Stig E. Bojesen, Bernardo Bonanni, Anne‐Lise Børresen‐Dale, Anikó Bozsik, Angela R. Bradbury, Judith S. Brand, Hiltrud Brauch, Hermann Brenner, Brigitte Bressac–de Paillerets, Carole Brewer, Louise A. Brinton, Per Broberg, Angela Brooks‐Wilson, Joan Brunet, Thomas Brüning, Barbara Burwinkel, Saundra S. Buys, Jinyoung Byun, Qiuyin Cai, Trinidad Caldés, Maria A. Caligo, Ian Campbell, Federico Canzian, Olivier Caron, Ãngel Carracedo, Brian D. Carter, Jose E. Castelao, Laurent Castéra, Virginie Caux‐Moncoutier, Salina Chan, Jenny Chang‐Claude, Stephen J. Chanock, Xiaoqing Chen, Ting‐Yuan David Cheng, Jocelyne Chiquette
S137905309. 2017475 CitationsOPEN ACCESS
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven, Ingrid A.M. Mandjes, Inge Kemper, Vincent O. Dezentjé, Irma M. Oving, Aafke H. Honkoop, Lidwine W. Tick, Agnès J. van de Wouw, Caroline M.P.W. Mandigers, Laurence J. van Warmerdam, Jelle Wesseling, Marie-Jeanne TFD Vrancken Peeters, Sabine C. Linn, Gabe S. Sonke
The Lancet Oncology. 2018455 CitationsOPEN ACCESS
Related on ScholarIQ
Leiden University Medical Center
Institution
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
Paper
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Paper
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.
Paper
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Paper
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
Paper